Genfit (GNFT) has released an update.
GENFIT, a biopharmaceutical company focusing on severe liver diseases, has announced its upcoming Combined Shareholders Meeting scheduled for May 22, 2024. Shareholders will have access to the meeting’s documents on the company’s website and can submit their votes via the VOTACCESS platform. GENFIT, known for its extensive work in liver disease research, has a diverse pipeline with programs in various development stages.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
